Skip to main content

Search Results

Paperwork

When the Insurance Says No to a Clinical Trial

As an LLS Clinical Trial Nurse Navigator, Ashley Giacobbi works tirelessly to connect the right patient with the right clinical trial – work that has become increasingly complicated in the COVID-19 era.

But recently, she went the extra mile to ensure a patient – a young healthcare worker whose AML had relapsed several times – could access a trial that offered a promising treatment option.

Blood Transfusion

Blood transfusion using cells donated by healthy volunteers can help replace red cells, platelets and other blood components. Some people with leukemia, lymphoma, myeloma and other blood diseases or disorders such as hereditary anemias and aplastic anemia need periodic blood transfusions for several reasons:

Low Blood Counts

Cancer therapy can lower your blood cell counts and chemotherapy especially can affect rapidly dividing bone marrow cells. This hinders the marrow's ability to supply new cells to the blood during treatment and for some time after. Patients receiving treatment for blood cancer can develop

Understanding Blood Counts

Blood cell counts give your doctor important clues about the state of your health before, during and after treatment. Blood counts alone can't determine whether you have a blood cancer, but they can alert your doctor if further testing is needed.

A complete blood count (CBC) is the number and types of cells circulating in your blood. Your CBC is measured using laboratory tests that require a small blood sample.

Blood is composed of several types of cells:

Coping With Cancer

When someone is diagnosed with cancer, everyone in his or her family is affected. This holds especially true when a child has cancer. Different families have different ways of coping, but there are some sound strategies that anyone can employ. For useful tools and tips that may help, see the following pages:

When Your Child Has Cancer

Hearing that your child has cancer is terrifying for any parent. Today, most childhood cancer patients can expect to have full and productive lives. Many childhood cancer survivors return to school, attend college, enter the workforce, marry and become parents. Nevertheless, being vigilant about follow-up care, being aware of long-term and late effects of treatment, helping your child return to school and even dealing with your emotions are all things you’ll need to manage.  

Cancer-Related Fatigue

Fatigue is very common in patients with blood cancers. Cancer-related fatigue (CRF) is characterized by excessive and persistent exhaustion that interferes with daily activity. CRF often begins before cancer is diagnosed, worsens during the course of treatment and may persist for months—even years—after treatment ends. 

Firefighters and Cancer Risk

Firefighters are at an increased risk of developing cancer. There are steps to take that can reduce that risk.

All firefighters, regardless whether they are career or volunteer, put their own lives at risk to save others in their communities. In addition to the danger of putting out fires, firefighters are at an increased risk for different types of cancer due to the smoke and hazardous chemicals they are exposed to in the line of duty. There have been multiple studies that show this increased risk for cancer.  

Prevention of myeloid cancers by understanding their pre-clinical evolution

Here we propose to study blood DNA from 1500 people who have had extensive genetic and aging-related tests over many years as participants of the "Immunoageing" study (<a href="http://www.immunoageing.eu/index.html">http://www.immunoageing.eu/index.html</a>). We propose to study these people for the presence of age-related clonal hematopoiesis (ARCH) to understand what factors are associated with ARCH and its expansion.

Understanding Blood, Marrow and the Lymphatic System

Understanding your diagnosis will help you make informed decisions about your treatment, and give you a greater understanding of the scientific advances in blood cancer treatment and improvements in quality of life for survivors.

Knowing about normal blood and marrow and the lymphatic system can also help you better understand your diagnosis. 

211Astatine-CD123 Radioimmunotherapy for Cancer (Stem) Cell-Directed Treatment of Acute Leukemia

Because acute leukemias are very sensitive to radiation, radioisotopes are ideal payloads to arm antibodies against these difficult-to-cure, aggressive blood cancers. Here, we will develop fully human anti-CD123 antibodies carrying the highly potent alpha-emitter astatine-211 (211At) as a new therapy for acute leukemia.

Long-Term and Late Effects For Cancer Survivors

Blood cancer survivors don't always have serious long-term or late effects of treatment. For those who do, some long-term effects, such as fatigue, can linger for months or years after therapy. Late effects, such as medical conditions like heart disease and other cancers, don't appear until years after treatment ends. Effects can range from mild to severe.

Talk with your doctor about possible long-term and late effects. Your risk for developing long-term or late effects can be influenced by your:

Follow-Up Care For Childhood Cancer Survivors

Survivorship Workbook

Use this Survivorship Workbook to collect all the important information you need throughout diagnosis, treatment, follow-up care and long-term management of a blood cancer.

Long-Term And Late Effects Of Treatment For Childhood Cancer Survivors

Treatment for childhood blood cancer may consist of chemotherapy and other drug therapies and may also include radiation therapy or allogeneic stem cell transplantation. There are risks for long-term and late effects common to all of these treatments, and these may include problems with learning, fatigue, bone or joint pain and an increased risk for developing a secondary cancer. 

Uncovering the role of TCL1A as a driver of clonal hematopoiesis and hematological malignancies

Mutations in a diverse set of genes can lead to pre-cancerous expansion of blood stem cells, but the factors that mediate the growth of these mutant clones are unknown. We recently discovered that many of these mutations lead to abnormal activation of a gene called TCL1A. Consequently, TCL1A may be an attractive target for treating or preventing blood cancers, but little is known about its function. Here, we will uncover how TCL1A influences the biology of pre-cancerous blood stem cells.

Health Insurance and End-of-Life Care for People with Hematologic Malignancies

Patients with blood cancers from racial and ethnic minority groups are more likely to experience suboptimal end-of-life (EOL) care. These disparities may be partially driven by health insurance differences but there is limited research examining insurance access as a potential contributor to EOL care disparities for this population. We will leverage complementary local and national datasets to assess the relationship between insurance status and type with EOL quality measures.